by Madaline Spencer | Dec 3, 2025
Jonathan Strober, MD, pediatric neurologist and neuromuscular specialist at the University of California at San Francisco, discusses the use of nipocalimab in adolescent patients with generalized myasthenia gravis (gMG). gMG is a chronic autoimmune...
by Madaline Spencer | Dec 2, 2025
Michael A. Levine, MD, ML, Children’s Hospital of Philadelphia, discusses positive topline results from the CALIBRATE trial of encaleret in patients with autosomal dominant hypocalcemia type 1 (ADH1). ADH1 is a rare form of hypoparathyroidism caused by...
by Madaline Spencer | Dec 1, 2025
Nolan Campbell, PhD, U.S. Medical Director at Johnson & Johnson, discusses the EPIC clinical trial design that will evaluate the efficacy of nipocalimab versus efgartigimod in patients with generalized myasthenia gravis (gMG). gMG is a chronic...
by Madaline Spencer | Nov 26, 2025
Sindhu Ramchandren, MD, Executive Medical Director of Neuroscience at Johnson & Johnson, discusses long-term efficacy of nipocalimab in patients with generalized myasthenia gravis (gMG). gMG is a chronic autoimmune neuromuscular disease characterized...
by Madaline Spencer | Nov 25, 2025
The U.S. Food and Drug Administration (FDA) has approved Koselugo (selumetinib) for the treatment of adult patients with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). Selumetinib was first approved in 2020 for pediatric...
